Relative Risk vs Absolute Risk: How Medical Headlines Change the Number

Use trial event counts to calculate absolute risk, relative risk and number needed to treat—and spot misleading medical headlines.

Two clinical trial groups compared with outcome counts, percentage bars and uncertainty intervals
Illustration by Future & Fact.

Science · Numbers guide. Relative risk describes a proportional change between groups. Absolute risk describes the actual difference in event rates. A treatment that reduces an outcome from 2 people in 100 to 1 in 100 produces a 50% relative reduction and a 1-percentage-point absolute reduction. Both are mathematically correct; the absolute numbers reveal the scale.

This guide shows how to reconstruct a medical headline from the trial counts behind it. It explains event rates, absolute and relative changes, number needed to treat, time periods and uncertainty. It is general reporting guidance, not an assessment of an individual’s care.

Start with two event rates

Suppose a fictional randomized trial follows 10,000 people in a treatment group and 10,000 in a control group for one year. The reported outcome occurs in 100 treated participants and 200 control participants.

  • Treatment event rate: 100 ÷ 10,000 = 1%.
  • Control event rate: 200 ÷ 10,000 = 2%.

Those two rates are the foundation. Keep the denominator, outcome definition and follow-up period attached. “100 events” means something different in a group of 1,000 than in a group of 100,000.

Calculate the absolute risk difference

Subtract the treatment rate from the control rate:

2% − 1% = 1 percentage point.

This is the absolute risk reduction in the fictional trial. Expressed as natural frequencies, the groups differ by one event per 100 people over one year. Do not call the change “1%” without clarifying whether you mean one percent of the starting risk or one percentage point.

Calculate the relative risk reduction

Divide the absolute reduction by the control rate:

(2% − 1%) ÷ 2% = 50%.

The treatment group experienced half the event rate of the control group, a 50% relative reduction. Relative framing makes the proportional effect visible. By itself it does not tell readers whether the event changed from 40% to 20%, 2% to 1%, or 0.02% to 0.01%.

The U.S. Food and Drug Administration’s evidence-based guide to communicating risks and benefits recommends providing absolute risks rather than relative figures alone because relative framing can unduly influence decisions.

Number needed to treat is another view of the absolute difference

For a beneficial outcome, divide one by the absolute reduction expressed as a decimal:

1 ÷ 0.01 = 100.

In the fictional example, 100 people would need to receive the treatment for one year to prevent one additional event compared with control, assuming the trial estimate applies. This number needed to treat is tied to the outcome and time period. It should not be quoted without them.

For harms, a similar calculation can describe the number needed to harm. Benefits and harms can have different denominators, severity and timing, so a single number does not replace a benefit-risk assessment.

Use the randomized denominator, not only participants who finished

Trial reports can analyze all randomized participants according to their assigned group, a principle commonly called intention to treat, or use other analysis populations defined in the protocol. Excluding participants after randomization can change comparability between groups.

Record which population produced the headline result. Also check missing data, withdrawals and whether the outcome was measured equally in both groups. A clean percentage can hide a complicated denominator.

A positive endpoint is not the entire benefit-risk decision

A trial may specify one primary endpoint and several secondary endpoints. The protocol and statistical analysis plan explain how they will be tested. A favorable change in one measure does not automatically establish every claimed benefit, and a surrogate measurement may not be the same as a patient outcome.

FDA explains that medical products have both benefits and risks and that clinical trials cannot identify every safety problem before broader use. Coverage should therefore report important adverse outcomes and uncertainty alongside the headline benefit rather than placing them in an unrelated final paragraph.

Confidence intervals show the range supported by the data

An event-rate difference is an estimate from a sample. A confidence interval communicates statistical uncertainty under the analysis method. If the interval is wide, the true effect compatible with the data can range from modest to large. If it crosses the no-difference value, the result requires especially careful description.

Statistical uncertainty is not the only limit. A precise estimate can still apply to a narrow population, short follow-up or outcome that matters differently outside the trial. Preserve eligibility criteria and duration.

Risk ratio, odds ratio and hazard ratio are not interchangeable

A risk ratio compares event proportions over a stated period. An odds ratio compares the odds of an event, which are the probability of the event divided by the probability of no event. When outcomes are common, an odds ratio can look farther from one than the corresponding risk ratio.

A hazard ratio comes from time-to-event analysis and compares estimated event rates over the follow-up under model assumptions. A hazard ratio of 0.5 does not by itself mean that exactly half as many participants experienced the outcome by the end of the study. Look for cumulative event rates or survival estimates at a meaningful time point.

If a press release says “reduced risk” while the paper reports an odds ratio or hazard ratio, use the study’s term and add absolute event information. Do not convert between measures without the required baseline data and analysis.

Benefits and harms need the same denominator discipline

A report may highlight relative benefit while listing harms only as raw counts, or do the reverse. Put each important outcome into comparable group rates over comparable periods. Separate serious events from mild events and prespecified safety outcomes from signals found after looking through many categories.

FDA’s guidance on presenting quantitative efficacy and risk information discusses absolute frequencies and percentages as formats readers can understand more readily than relative frequencies alone. A useful table therefore gives both group counts, both percentages and the absolute difference before adding a relative measure.

Do not subtract unlike outcomes into a single “net benefit” unless the study defines and justifies that composite. Preventing one severe outcome and causing one mild side effect are not numerically interchangeable merely because both involve one participant.

A second worked example shows why baseline risk matters

Imagine another one-year study where an outcome falls from 0.02% to 0.01%. That is also a 50% relative reduction. The absolute reduction is 0.01 percentage points—one fewer event per 10,000 people—and the corresponding number needed to treat is 10,000 for one year.

The same relative percentage can therefore describe very different absolute effects. Neither example tells an individual what choice to make; it shows why a news report should give both group rates and the relevant period.

Confirmed, inferred and unknown

Confirmed: the report provides participant counts, event definitions, follow-up, group rates and prespecified analyses.

Inferred: researchers estimate that the intervention caused the between-group difference under the trial design. Generalizing beyond the studied population requires additional reasoning and evidence.

Unknown: uncommon or delayed outcomes may remain uncertain, and results can differ in populations excluded from the trial or in routine use.

A medical-headline checklist

  1. Write the treatment and control event counts with denominators.
  2. Calculate both absolute and relative differences.
  3. Name the outcome and follow-up period.
  4. Check the prespecified primary endpoint and analysis population.
  5. Report confidence intervals and important harms.
  6. Separate a trial result from regulatory approval and from advice for an individual.

Sources and method

Future & Fact used FDA guidance on communicating quantitative benefit and risk information and the standard arithmetic shown above. The examples are fictional so readers can reproduce each calculation; they do not describe a real product.

Published October 6, 2026. Related reading: How Clinical Trials Work and How Scientific Evidence Works.

The Future & Fact newsletter

Fresh discoveries.
Delivered to your inbox.

Explore AI, science and space with clear explanations and stories grounded in primary sources.

Coming soon — signups are not open yet.

Read our Privacy Policy for information about how we handle personal data.